Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.
Paul Melmeyer with the National Organization for Rare Disorders explains the provisions of the Orphan Drug Act, how it creates incentives for the development of new treatments and why patients living with rare diseases continue to support the law.